Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Flexion Therapeutics, Inc. (NASDAQ: FLXN).

Full DD Report for FLXN

You must become a subscriber to view this report.


Recent News from (NASDAQ: FLXN)

Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q3 2018 Results - Earnings Call Transcript
Flexion Therapeutics Inc. (FLXN) Q3 2018 Earnings Conference Call November 7, 2018 4:30 PM ET Executives Scott Young – Vice President-Corporate Communications and Investor Relations Michael Clayman – Chief Executive Officer Dan Deardorf – Senior Vice Preside...
Source: SeekingAlpha
Date: November, 07 2018 21:26
Flexion Therapeutics beats by $0.04, beats on revenue
Flexion Therapeutics (NASDAQ: FLXN ): Q3 GAAP EPS of -$1.15 beats by $0.04 . Revenue of $7M beats by $0.3M . Shares -2.1% . Press Release More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 07 2018 16:25
Flexion Therapeutics Reports Third-Quarter 2018 Financial Results and Recent Business Highlights
Company reported net ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) sales of $7.0 million in Q3 representing 84% growth over Q2 Strong progress in Commercial activities: 79% of target accounts have purchased, or received samples of, ZILRETTA and...
Source: GlobeNewswire
Date: November, 07 2018 16:01
Centrexion Therapeutics Seeks $75 Million In Proposed IPO
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h...
Source: SeekingAlpha
Date: November, 05 2018 13:56
Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019
BURLINGTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a product-specific J code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension). Under t...
Source: GlobeNewswire
Date: November, 05 2018 06:30
Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018
BURLINGTON, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2018 financial results after the close of the U.S. financial markets on Wednesday, November 7, 2018. Flexion’s management will...
Source: GlobeNewswire
Date: October, 31 2018 07:30
Centrexion Therapeutics Begins U.S. IPO Effort
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca...
Source: SeekingAlpha
Date: October, 25 2018 16:11
Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting
Data presented at 2018 American College of Rheumatology (ACR) Annual Meeting show concurrent, bilateral administration of ZILRETTA appeared safe and well tolerated Systemic exposure to triamcinolone acetonide was 10-fold lower with ZILRETTA compared to traditional immediate-release ...
Source: GlobeNewswire
Date: October, 22 2018 07:30
Flexion Is Flexible With The Data, Rigid With The Price
Summary Flexion ( FLXN ) has developed and won approval for ZILRETTA (Triamcinolone acetonide extended-release, TA-ER) for osteoarthritis-related knee pain; Zilretta is Flexion’s only approved product. Outside of Zilretta, the pipeline for Flexion is essentially barren; the company&...
Source: SeekingAlpha
Date: October, 17 2018 09:30
Factors of Influence in 2018, Key Indicators and Opportunity within Iamgold, Mazor Robotics, Flexion Therapeutics, Hemisphere Media Group, Criteo S.A, and EP Energy - New Research Emphasizes Economic Growth
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Iamgold Corporation (NYSE:IAG), Mazor Robotics Ltd. (NASDAQ:MZOR), Fle...
Source: GlobeNewswire
Date: October, 16 2018 08:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1826.5626.6426.8625.95672,590
2018-05-1726.5626.6426.8625.95672,590
2017-05-1618.4318.0718.5417.55818,406
2017-05-1519.4118.2919.5318.25650,940
2017-05-1219.4419.3119.5019.03434,313

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1452,610106,97749.1788Short
2018-12-1376,145213,27235.7032Short
2018-12-1232,41797,82933.1364Cover
2018-12-1134,583142,35224.2940Cover
2018-12-1042,855135,36631.6586Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FLXN.


About Flexion Therapeutics, Inc. (NASDAQ: FLXN)

Logo for Flexion Therapeutics, Inc. (NASDAQ: FLXN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: FLXN)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 08 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 08 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 08 2018

       

       


      Daily Technical Chart for (NASDAQ: FLXN)

      Daily Technical Chart for (NASDAQ: FLXN)


      Stay tuned for daily updates and more on (NASDAQ: FLXN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: FLXN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FLXN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of FLXN and does not buy, sell, or trade any shares of FLXN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/